2617 Bissonnet Street
Suite 225
Houston, TX 77005
United States
346 355 4099
https://www.alaunos.com
Sektor(en):
Branche:
Vollzeitmitarbeiter: 1
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Dale Curtis Hogue Jr. | Interim CEO & Director | N/A | N/A | 1970 |
Ms. Melinda Lackey | Senior VP of Legal, Administration & Secretary | 580,43k | N/A | 1977 |
Mr. Michael Wong | Vice President of Finance & Principal Accounting Officer | N/A | N/A | 1980 |
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
Alaunos Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 6. Die grundlegenden Scores sind Audit: 9, Vorstand: 6, Shareholderrechte: 3, Kompensation: 9.